GoodRx Holdings 배당금 및 환매

GDRX 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (GDRX)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Healthcare Services)	1.0%
애널리스트 예측 (GDRX) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GDRX 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GDRX 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GDRX 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: GDRX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

GoodRx Holdings 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Price target decreased by 8.7% to US$8.65

GoodRx Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024

GoodRx Unveils New E-Commerce Platform, Launches with Opill

GoodRx Announces Exclusive Low Cash Price for QSYMIA, the Leading Branded Once-Daily Oral Weight Management Medication for Adults

GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Shares May Have Run Too Fast Too Soon

GoodRx: The Tide Is Turning The Wrong Way (Rating Downgrade)

GoodRx Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Key Executive exercised options and sold US$252k worth of stock

GoodRx Holdings: Failing To Gain Much Traction

GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

Key Executive exercised options and sold US$276k worth of stock

Chief Accounting Officer recently sold US$535k worth of stock

Key Executive exercised options and sold US$308k worth of stock

GoodRx Holdings, Inc. Revises Earnings Guidance for the Full Year 2024

GoodRx Q2 Earnings Preview

Boehringer Ingelheim and Goodrx Announce Exclusive Patient Affordability Initiative for Adalimumab-Adbm Injection, Boehringer's Biosimilar to Humira®

GoodRx Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

GoodRx Holdings (NASDAQ:GDRX) Could Easily Take On More Debt

GoodRx Holdings, Inc. Announces the Election of Ian T. Clark to its Board of Directors

Key Executive exercised options and sold US$280k worth of stock

GoodRx Launches New "Prescription Cost Tracker" to Spotlight Key Factors Driving Out-Of-Pocket Medication Costs in the U.S

Key Executive exercised options and sold US$306k worth of stock

GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 30% Price Boost Is Out Of Tune With Revenues

Returns On Capital At GoodRx Holdings (NASDAQ:GDRX) Paint A Concerning Picture

GoodRx Holdings, Inc Announces Board and Committee Changes

GoodRx: Encouraging Profit Stabilization (Rating Upgrade)

Price target increased by 7.5% to US$9.40

GoodRx Holdings, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

First quarter 2024 earnings released: US$0.003 loss per share (vs US$0.008 loss in 1Q 2023)

GoodRx Holdings, Inc., Annual General Meeting, Jun 06, 2024

Kessler Topaz Meltzer & Check, LLP Files A Securities Fraud Class Action Lawsuit Against GoodRX Holdings, Inc

GoodRx Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

GoodRx Holdings: Large TAM Continues To Support Growth

GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Price target increased by 15% to US$8.21

Is GoodRx Holdings, Inc. (NASDAQ:GDRX) Trading At A 24% Discount?

Goodrx Holdings, Inc. Provides Revenue Guidance for First Quarter 2024 and Fiscal Year 2024

GoodRx Holdings (NASDAQ:GDRX) Has A Rock Solid Balance Sheet

GoodRx: Cost Saving Is A Strong Value Proposition To Consumers

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Consensus EPS estimates upgraded to US$0.0037 loss

GoodRx Holdings, Inc. Announces Executive Changes

Consensus EPS estimates upgraded to US$0.0047 loss

GoodRx Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GoodRx Stock Spikes After Receiving A Strong Dose Of Performance

GoodRx Holdings, Inc. Revises Earnings Guidance for the Fourth Quarter and Year Ended December 31, 2023

GoodRx Holdings, Inc. Appoints Kelly J. Kennedy to Its Board of Directors

What Is GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Share Price Doing?

Chief Operating Officer exercised options and sold US$263k worth of stock

Interim Chief Executive Officer recently bought US$677k worth of stock

Consensus EPS estimates fall from profit to US$0.013 loss

Price target decreased by 11% to US$7.50

Goodrx Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

New minor risk - Shareholder dilution

GoodRx Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

GoodRx Launches Real-Time Benefit Check in Provider Mode to Offer Comprehensive Cost Information at the Point of Prescribing

Consensus EPS estimates increase by 59%

Chief Operating Officer exercised options and sold US$338k worth of stock

Price target increased by 18% to US$8.00

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Goodrx Holdings, Inc. Provides Revenue Guidance for the Third Quarter and Full Year 2023

New minor risk - Share price stability

An Intrinsic Calculation For GoodRx Holdings, Inc. (NASDAQ:GDRX) Suggests It's 41% Undervalued

GoodRx Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Goodrx Appoints Dorothy Gemmell as Chief Commercial Officer

Agile Therapeutics, Inc. (NasdaqCM:AGRX) announced an agreement to acquire vitaCare Prescription Services, Inc. from GoodRx Holdings, Inc. (NasdaqGS:GDRX).

Goodrx Holdings, Inc. Announces Resignation of Jacqueline Kosecoff as Member of the Board, Effective June 30, 2023

Goodrx Holdings Notifies the Listing Qualifications Department of the Nasdaq Regarding Non Compliance with Nasdaq Listing Rule 5605(c)(2)(A)

GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

Chief Operating Officer exercised options and sold US$222k worth of stock

Consensus EPS estimates fall by 18%

Price target decreased by 7.1% to US$6.41

Consensus EPS estimates upgraded to US$0.03 loss, revenue downgraded